SANCUSO (granisetron) by Cumberland Pharmaceuticals is serotonin 3 receptor antagonists [moa]. First approved in 2008.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
SANCUSO is a transdermal extended-release film formulation of granisetron, a serotonin-3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). It delivers medication through the skin over several days, offering convenience compared to oral or IV alternatives. The drug works by blocking serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract.
Product is approaching loss of exclusivity with modest Medicare spending (~$7M in 2023), signaling a small, specialized team focused on defending market position against generics.
Serotonin 3 Receptor Antagonists
Serotonin-3 Receptor Antagonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study in Healthy Chinese Subjects Comparing SP-01 (Granisetron Patch) Manufactured at Two Different Sites
Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.
Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting
Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
Worked on SANCUSO at Cumberland Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on SANCUSO offers limited growth opportunity as the product is in LOE-approaching stage with modest market size (~$7M Part D spending, 3,201 claims in 2023). Career value lies primarily in defensive commercial execution, generic transition planning, and specialty oncology market expertise rather than brand-building or expansion.